Association between telomere length and CYP19 TTTA repetition polymorphism in healthy and breast cancer-diagnosed women

Figures & data

Figure 1 CYP19 aromatase polymorphism frequency by number of repeats in BC-diagnosed women.

Abbreviation: BC, breast cancer.

Table 1 Clinical parameters of BC-diagnosed women and healthy women.

Clinical parameter	BC-diagnosed women (n = 70)	Healthy women (n = 180)	p
Age (years)	58.74 ± 12	59.0 ± 11	0.88
BMI (kg/m^2)	30 ± 7.1	29.8 ± 7.1	0.92
Hormonal levels
Estradiol (pg/mL)	19.89 ± 5.96	17.6 ± 9.6	0.09
FSH (UI/L)	43.90 ± 18.99	58.3 ± 5.6	0.06
Estrone (pg/mL)	25.4 ± 4.8	37.5 ± 12.0	0.17
Clinical stage, n (%)
I	4.28 (3)
II	37.14 (26)
III	41.42 (29)
IV	17.14 (12)
Histologic grade, n (%)
1 and 2	14 (20)
3	56 (80)
Histologic type, n (%)
Ductal	42 (60.0)
Lobular	17 (24.2)
Others	11 (5.7)
Hormonal receptors positive (%)
Estrogen	88
Progesterone	89

Abbreviations: BC, breast cancer; BMI, body mass index; FSH, follicle-stimulating hormone.

Figure 2 CYP19 aromatase polymorphism frequency by number of repeats in healthy women.

Figure 3 CYP19 aromatase polymorphism frequency by number of repeats (acrylamide gel 10% with 7 M of urea).

Note: Lane 1: homozygote (TTTA)7, lane 2: heterozygote (TTTA)7/(TTTA)8, lane 3: heterozygote (TTTA)6/(TTTA)7, lane 4: heterozygote (TTTA)6/(TTTA)10, lane 5: homozygote (TTTA)6 and lane 6: allelic marker.

Figure 4 Telomere length comparison between healthy women (group 1) and BC-diagnosed women (group 2).

Notes: Significant difference is shown between groups (calculated using Mann–Whitney U test). p < 0.05 was considered significant.
Abbreviations: BC, breast cancer; Min, minimum, Max, maximum.

Figure 5 The relationship between telomere length and serum levels of (A) estradiol (pg/mL) and (B) estrone (pg/mL) in healthy women.